CL2016000583A1 - Mandelato de atrasentan; formas cristalinas anhidra e hidratada de s-mandelato, y anhidra de r-mandelato de atrasentan; composición farmacéutica que las comprende; y su uso para tratar una enfermedad renal crónica. - Google Patents
Mandelato de atrasentan; formas cristalinas anhidra e hidratada de s-mandelato, y anhidra de r-mandelato de atrasentan; composición farmacéutica que las comprende; y su uso para tratar una enfermedad renal crónica.Info
- Publication number
- CL2016000583A1 CL2016000583A1 CL2016000583A CL2016000583A CL2016000583A1 CL 2016000583 A1 CL2016000583 A1 CL 2016000583A1 CL 2016000583 A CL2016000583 A CL 2016000583A CL 2016000583 A CL2016000583 A CL 2016000583A CL 2016000583 A1 CL2016000583 A1 CL 2016000583A1
- Authority
- CL
- Chile
- Prior art keywords
- mandelato
- atrasentan
- anhydrous
- pharmaceutical composition
- kidney disease
- Prior art date
Links
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 title abstract 3
- 229950010993 atrasentan Drugs 0.000 title abstract 3
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical class [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
- C07C59/50—Mandelic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361877101P | 2013-09-12 | 2013-09-12 | |
| US14/133,297 US8962675B1 (en) | 2013-09-12 | 2013-12-18 | Atrasentan mandelate salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016000583A1 true CL2016000583A1 (es) | 2016-11-11 |
Family
ID=52472936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016000583A CL2016000583A1 (es) | 2013-09-12 | 2016-03-11 | Mandelato de atrasentan; formas cristalinas anhidra e hidratada de s-mandelato, y anhidra de r-mandelato de atrasentan; composición farmacéutica que las comprende; y su uso para tratar una enfermedad renal crónica. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8962675B1 (https=) |
| EP (2) | EP3044222B1 (https=) |
| JP (1) | JP2016530311A (https=) |
| CN (1) | CN105745204A (https=) |
| AU (1) | AU2014318924A1 (https=) |
| CA (1) | CA2923627C (https=) |
| CL (1) | CL2016000583A1 (https=) |
| MX (1) | MX2016003065A (https=) |
| WO (1) | WO2015038571A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2916033C (en) * | 2013-07-08 | 2022-08-23 | Abbvie Inc. | Stabilized pharmaceutical dosage forms comprising atrasentan |
| CN105905245B (zh) * | 2016-06-03 | 2018-12-25 | 青岛北海船舶重工有限责任公司 | 用于水面无人艇布放回收的吊笼 |
| US20220304979A1 (en) * | 2019-12-17 | 2022-09-29 | Chinook Therapeutics, Inc. | Methods of reducing disease flares |
| KR20230015874A (ko) * | 2019-12-17 | 2023-01-31 | 치누크 세라퓨틱스, 인크. | 아트라센탄에 의해 iga 신장병증을 치료하는 방법 |
| CN115803028A (zh) | 2020-07-10 | 2023-03-14 | 阿斯利康(瑞典)有限公司 | 用于治疗慢性肾病的齐泊腾坦和达格列净的组合 |
| EP4608396A1 (en) | 2022-10-28 | 2025-09-03 | Chinook Therapeutics, Inc. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| CA2195677C (en) * | 1994-08-19 | 2005-11-08 | Martin Winn | Endothelin antagonists |
| US7208517B1 (en) * | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| US7365093B2 (en) | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| US5767144A (en) | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
| US6124341A (en) | 1996-02-13 | 2000-09-26 | Abbott Laboratories | Endothelin antagonists |
| US5801250A (en) | 1996-12-13 | 1998-09-01 | Abbott Laboratories | Process for the stereoselective production of nitro-enamine compounds |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP1114022A1 (en) | 1998-09-14 | 2001-07-11 | Abbott Laboratories | Process for producing stereoselective nitro compounds |
| US20020055457A1 (en) | 2000-08-07 | 2002-05-09 | Janus Todd J. | Methods of treating cancer and the pain associated therewith using endothelin antagonists |
| WO2002017912A1 (en) * | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| US20030022811A1 (en) | 2001-04-11 | 2003-01-30 | Amitabh Singh | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| US20030092757A1 (en) | 2001-04-11 | 2003-05-15 | Amitabh Singh | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| UA79248C2 (en) * | 2001-11-09 | 2007-06-11 | Janssen Pharmaceutica Nv | Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| CA2578824A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 2 of atrasentan hydrochloride |
| WO2006034234A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 3 of atrasentan hydrochloride |
| WO2006034085A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form of atrasentan hydrochloride |
| WO2006034094A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 1 of atrasentan hxdrochloride |
| US20080132710A1 (en) | 2006-12-04 | 2008-06-05 | Abbott Laboratories | Atrasentan hydrochloride crystalline form 2 |
| US20110086103A1 (en) * | 2008-04-04 | 2011-04-14 | Actavis Group Ptc Ehf | Novel mandelate salt of fesoterodine |
| US20100184026A1 (en) | 2009-01-22 | 2010-07-22 | Abbott Laboratories | Companion Diagnostic Assays For Endothelin Receptor Antagonists |
-
2013
- 2013-12-18 US US14/133,297 patent/US8962675B1/en active Active
-
2014
- 2014-09-10 EP EP14780663.2A patent/EP3044222B1/en not_active Not-in-force
- 2014-09-10 CA CA2923627A patent/CA2923627C/en active Active
- 2014-09-10 EP EP17172157.4A patent/EP3239148A1/en not_active Withdrawn
- 2014-09-10 MX MX2016003065A patent/MX2016003065A/es unknown
- 2014-09-10 WO PCT/US2014/054888 patent/WO2015038571A1/en not_active Ceased
- 2014-09-10 JP JP2016542052A patent/JP2016530311A/ja active Pending
- 2014-09-10 CN CN201480061886.9A patent/CN105745204A/zh active Pending
- 2014-09-10 AU AU2014318924A patent/AU2014318924A1/en not_active Abandoned
-
2015
- 2015-01-12 US US14/594,742 patent/US9637476B2/en active Active
-
2016
- 2016-03-11 CL CL2016000583A patent/CL2016000583A1/es unknown
-
2017
- 2017-03-21 US US15/464,455 patent/US20170190692A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016530311A (ja) | 2016-09-29 |
| US8962675B1 (en) | 2015-02-24 |
| US20170190692A1 (en) | 2017-07-06 |
| CN105745204A (zh) | 2016-07-06 |
| CA2923627A1 (en) | 2015-03-19 |
| EP3044222A1 (en) | 2016-07-20 |
| AU2014318924A1 (en) | 2016-03-17 |
| MX2016003065A (es) | 2016-05-26 |
| EP3239148A1 (en) | 2017-11-01 |
| US9637476B2 (en) | 2017-05-02 |
| CA2923627C (en) | 2022-06-21 |
| US20150073031A1 (en) | 2015-03-12 |
| US20150126574A1 (en) | 2015-05-07 |
| WO2015038571A1 (en) | 2015-03-19 |
| EP3044222B1 (en) | 2017-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003358A1 (es) | Uso de un fumarato para preparar un medicamento útil para tratar esclerosis múltiple. | |
| CL2015003690A1 (es) | Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington. | |
| CL2016000583A1 (es) | Mandelato de atrasentan; formas cristalinas anhidra e hidratada de s-mandelato, y anhidra de r-mandelato de atrasentan; composición farmacéutica que las comprende; y su uso para tratar una enfermedad renal crónica. | |
| EA201690087A1 (ru) | Новые квиназолиноны как ингибиторы бромодомена | |
| CL2016000238A1 (es) | Polimorfo de los inhibidores de la syk | |
| BR112013018953A2 (pt) | composição efervescente na forma sólida para uso em aplicações vaginais para o tratamento de infecções vaginais. | |
| HUE054672T2 (hu) | TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek | |
| DK3030323T3 (da) | Kdm1a-inhibitorer til behandlingen af sygdom | |
| CL2015000744A1 (es) | Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer. | |
| BR112013029773A2 (pt) | canabinoides para uso no tratamento de dor neuropática | |
| CL2015002801A1 (es) | Métodos para tratar la osteogénesis imperfecta. | |
| MX377534B (es) | Compuestos para usarse en el tratamiento de hiperinsulinemia. | |
| EP2964402A4 (en) | BIOMASS PROCESSING USING IONIC LIQUIDS | |
| IL256206A (en) | Mct4 inhibitors for treating disease | |
| PL3236935T3 (pl) | Farmaceutyczna postać dawkowania do zastosowania na błony śluzowe | |
| CL2015002488A1 (es) | Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen | |
| BR112015008113A2 (pt) | novo processo para preparar compostos para uso no tratamento de câncer. | |
| BR112017002318A2 (pt) | combinações de fármacos para tratar mieloma múltiplo. | |
| MX2019009539A (es) | Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b ( ptp1b). | |
| LT2981303T (lt) | Užpildo kompozicija lipoatrofijos gydymui | |
| EP2950976A4 (en) | CUTTING, POLISHING AND COLOR TREATMENT FLUIDS FOR CONCRETE | |
| DK3125874T3 (da) | Et terapeutisk middel til anvendelse i behandlingen af infektioner | |
| BR112017001384A2 (pt) | composto para uso em tratamento anti-helmíntico | |
| UY36250A (es) | Forma cristalina de sofosbuvir y proceso para su preparación | |
| DK2974728T3 (da) | Terapeutisk middel til meibomsk dysfunktion |